Navigation Links
Novel clinical trial aims to reduce recurrence of aggressive breast cancer
Date:3/8/2011

CLEVELAND In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center are exploring a new method to potentially prevent recurrence of an early stage, aggressive type of breast cancer. The pilot study, conducted by Joe Baar, MD, Director of Breast Cancer Research at UH Case Medical Center's Seidman Cancer Center, is recruiting patients with HER-2 neu+ breast cancer.

Patients with this form of breast cancer typically have a higher recurrence rate of nearly 25% following initial treatment. This novel study aims to improve outcomes through performing bone marrow biopsies to identify if patients' cancer has spread and adding an additional cancer-targeting drug to standard therapy.

"This study has the potential to change the standard of care for women with this type of breast cancer, which tends to spread very quickly," says Dr. Baar, who is also Associate Professor of Medicine at Case Western Reserve University School of Medicine. "A small number of HER-2 neu+ breast cancer patients do not do well following standard therapy. We are hoping to identify these high-risk patients and stop the cancer before it progresses to other parts of the body."

Traditional imaging, such as CT scans and bone scans, does not detect these microscopic metastases, which are small numbers of cancer cells that have spread from the breast to other areas of the body such as the bone marrow. Therefore, patients who are found to have such micrometastases in the bone marrow will receive the cancer-fighting drug Bevacizumab (Avastin) to rid the bone marrow of the micrometastases. The study is funded by Genentech through University Hospitals Case Medical Center.

"This important trial has the potential to really help this subset of women with HER-2 neu+ breast cancer who have a high rate of recurrence," says Stanton Gerson, MD, Director of the UH Seidman Cancer Center and the Case Comprehensive Cancer Center. "This innovative trial has the potential to lay the groundwork for a new standard of care for women with this aggressive form of breast cancer."


'/>"/>

Contact: Alicia Reale
alicia.reale@uhhospitals.org
216-844-5158
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. A novel prognostic marker for biliary atresia
2. Genome sequencing used to assess a novel form of Clostridium botulinum
3. Novel mechanism for control of gene expression revealed
4. Novel methods for improved breast cancer survival
5. Novel immune system-based gene therapy induces strong responses in metastatic melanoma, sarcoma
6. Novel surgery removes rare tumor, rebuilds trachea
7. Researchers reveal function of novel molecule that underlies human deafness
8. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
9. UCI researchers find novel memory-enhancing mechanism in brain
10. Novel imaging technique may reduce lymphedema in breast cancer patients
11. New standards of care and novel treatment options for several forms of lymphoma unveiled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), ... latest Artificial Intelligence (AI) thinking, announced today the launch of its revamped web ... essential information that offers a more comprehensive understanding of the organization’s business and ...
(Date:9/20/2017)... ... September 20, 2017 , ... On Thursday, the Triangle ... Work in the Research Triangle for 2017. , Winners were chosen based on ... meet a threshold in employee participation--a percentage that varies based upon the size ...
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added ... network of medical professionals working on a personal injury lien basis. Founded by Dr. ... brings these esteemed doctors’ vast experience with orthopedic injuries to patients in the Inland ...
(Date:9/20/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique is excited to ... Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include live ... Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that ... clinical and commercial support services market) has entered into an agreement on September ... , The PGSD is the first private Dental School to launch an ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
Breaking Medicine Technology: